Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have?

Academic Article

Abstract

  • © 2019 European Association of Urology Neoadjuvant chemotherapy has proven clinical benefit in muscle- invasive bladder cancer. Cisplatin is the likely driver of this benefit. Textbook definitions of cisplatin ineligibility may restrict almost 50% of patients from therapy. Checkpoint inhibitors (anti– PD-1 antibodies and anti– CTLA-4 antibodies) are currently in clinical trials for neoadjuvant use. Initial data from these studies appear promising.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Basu A; Sadeghi S
  • Start Page

  • 623
  • End Page

  • 626
  • Volume

  • 6
  • Issue

  • 4